Cancer treatment has made remarkable strides, yet a persistent hurdle remains: drug resistance. This occurs when cancer cells adapt and evolve, rendering previously effective treatments less potent or ineffective over time [1]. This phenomenon is a primary reason why systemic anticancer therapies may not achieve a cure or prolonged survival for many patients [1].
Understanding Cancer Drug Resistance
In clinical terms, drug-resistant disease is often synonymous with progressive disease, meaning the cancer has grown or spread since treatment began [1]. A more complex form, multidrug resistance (MDR), describes when cancer cells develop the ability to resist multiple treatments with distinct chemical structures and mechanisms of action [2, 7]. MDR is a substantial challenge in cancer therapy and, despite the benefits of various treatments, it inevitably occurs in most patients at some point during their disease course [2].
Research into cancer biology has revealed that drug resistance is a complex process driven by numerous molecular and cellular changes within cancer cells and their environment [7].
How Cancer Cells Develop Resistance
Cancer cells employ various mechanisms to evade the effects of anticancer drugs, whether they are traditional chemotherapies or newer targeted therapies [3, 7]. These mechanisms include:
- Increased Drug Efflux: Cancer cells can over-express proteins called efflux transporters, which act like pumps to remove anticancer drugs from inside the cell, reducing their concentration at the target site [3, 4, 7].
- Altered Drug Targets: The specific molecules within cancer cells that a drug is designed to hit can undergo changes (somatic alterations or mutations), making the drug unable to bind effectively [3, 7].
- Drug Inactivation: Cancer cells can develop ways to chemically modify or break down anticancer drugs, rendering them inactive [7].
- Deregulation of Apoptosis: Apoptosis, or programmed cell death, is a natural process that drugs often aim to trigger in cancer cells. Resistance can occur if cancer cells develop ways to bypass this process [3].
- Altered DNA Damage Repair: Some drugs work by damaging cancer cell DNA. Resistant cells can become more efficient at repairing this damage, allowing them to survive [7].
- Oncogenic Mutations: New mutations can arise that promote cancer cell survival and growth, even in the presence of therapy [7].
- Pharmacokinetic Issues: Factors related to how the body absorbs, distributes, metabolizes, and excretes the drug can also contribute to resistance [3].
For example, even highly successful targeted therapies like PARP inhibitors, which are used for certain types of tumors, often face the challenge of resistance developing over time [5].
Emerging Strategies to Overcome Resistance
While drug resistance remains a significant barrier, researchers are actively exploring new strategies to overcome it and improve patient outcomes:
- Drug Rechallenge and Treatment Continuation: Traditionally, treatment is stopped when cancer progresses [1]. However, for some patients, particularly those receiving molecularly targeted agents and immunotherapy, restarting a previously effective drug (rechallenge) or continuing treatment beyond initial progression are emerging as potential strategies [1].
- Nanotechnology Approaches: Nanoparticles, tiny drug-delivery systems, are showing promise in combating drug resistance, especially for targeted therapies [3, 4]. These therapeutic nanoparticles can enhance the effectiveness of drugs and potentially reduce side effects compared to conventional small molecule therapies [4].
- Synthetic Lethality: This innovative strategy focuses on exploiting specific genetic vulnerabilities in cancer cells. By targeting two genes or pathways that, when both are disrupted, lead to cell death, synthetic lethality can offer more selective and less toxic treatments. This approach can also delay the development of drug resistance and enhance therapeutic efficacy [6].
- Combination Therapies: Combining different types of treatments is a key strategy. For instance, carefully selected conventional therapies, such as certain chemotherapies, can be combined with immune checkpoint inhibitors (ICI) to prevent acquired resistance and improve the anti-tumor immune response [8].
Future Directions in Cancer Treatment
Despite a deeper understanding of the mechanisms behind multidrug resistance since its discovery in the 1960s, few strategies are currently available in routine clinical practice to combat it effectively [2]. A major challenge lies in systematically translating new knowledge from laboratory research into clinical applications [2].
Ongoing research continues to focus on unraveling the intricate processes of resistance and developing novel approaches, including advanced gene screening techniques, to identify new targets and treatment combinations [5, 6]. The ultimate goal is to develop more precise, effective, and less toxic therapies that can delay or overcome drug resistance, leading to improved clinical outcomes and preventing cancer relapse for patients [6].
Sources
- Rechallenge Strategy in Cancer Therapy. PubMed
- Understanding and overcoming multidrug resistance in cancer. PubMed
- Targeted cancer therapy; nanotechnology approaches for overcoming drug resistance. PubMed
- Therapeutic nanoparticles to combat cancer drug resistance. PubMed
- Understanding and overcoming resistance to PARP inhibitors in cancer therapy. PubMed
- The role of synthetic lethality in overcoming cancer therapy resistance: Emerging paradigm and recent advances. PubMed
- Molecular and cellular paradigms of multidrug resistance in cancer. PubMed
- Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors? PubMed